Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul 7;11(4):324-333.
doi: 10.1093/ehjcvp/pvaf014.

Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study

Sih-Yao Chen  1 , Jheng-Yan Wu  2   3 , Kuang-Ming Liao  4   5 , Yu-Min Lin  6
Affiliations
Observational Study

Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study

Sih-Yao Chen et al. Eur Heart J Cardiovasc Pharmacother. .

Abstract

Aims: Managing patients with atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) is challenging. While sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) show cardiovascular benefits, the impact of combining these agents is unclear. This study evaluated whether adding GLP-1 RA to SGLT2i provides additional benefits in patients with both ASCVD and HF.

Methods and results: This retrospective observational study utilized the TriNetX database to analyse patients with ASCVD and HF who initiated GLP-1 RA with SGLT2i or SGLT2i alone from 1 August 2016 to 30 September 2024. A total of 2 797 317 patients were identified, with 96 051 patients meeting inclusion criteria. After propensity score matching, 5272 patients in each group were analysed. Primary outcomes included mortality or hospitalization within 1 year; secondary outcomes examined mortality, hospitalization, and heart failure exacerbation (HFE). Patients receiving GLP-1RA and SGLT2i therapies had significantly lower risk of mortality or hospitalization [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.74-0.83], mortality (HR 0.72; 95% CI 0.62-0.84), hospitalization (HR 0.78; 95% CI 0.73-0.83), and HFE (HR 0.77; 95% CI 0.72-0.83) vs. SGLT2i alone. Subgroup analyses showed consistent benefits in patients with HFpEF, HFrEF, patients with diabetes, obesity, chronic kidney disease, or those using semaglutide or dulaglutide, while liraglutide use showed a neutral effect. Drug-related side effects were monitored as safety outcomes, which showed no significant differences between groups.

Conclusions: In ASCVD and HF patients, adding GLP-1 RA to SGLT2i reduces 1-year mortality and hospitalization, warranting further investigation in diverse settings.

Keywords: ASCVD; GLP-1RA; Heart failure; MACE; SGLT2i.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Flow diagram of cohort construction. Abbreviations: ASCVD, atherosclerotic cardiovascular disease; HF, heart failure; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium–glucose transport protein 2 inhibitors. *Study medications: GLP-1 RA with SGLT2i or SGLT2i alone.
Figure 2
Figure 2
This Kaplan–Meier survival curve compares patients with ASCVD and HF treated with GLP-1 RA combined with SGLT2i vs. those treated with SGLT2i alone. The GLP-1 RA and SGLT2i group demonstrate a significantly lower event rate over the 1-year follow-up compared to the SGLT2i alone group. ASCVD, atherosclerotic cardiovascular disease; HF, heart failure; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose transport protein 2 inhibitors.
See this image and copyright information in PMC

References

    1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, De Backer G, Regitz-Zagrosek V, Aamodt AH, Abdelhamid M, Aboyans V, Albus C, Asteggiano R, Bäck M, Borger MA, Brotons C, Čelutkienė J, Cifkova R, Cikes M, Cosentino F, Dagres N, De Backer T, De Bacquer D, Delgado V, Den Ruijter H, Dendale P, Drexel H, Falk V, Fauchier L, Ference BA, Ferrières J, Ferrini M, Fisher M, Fliser D, Fras Z, Gaita D, Giampaoli S, Gielen S, Graham I, Jennings C, Jorgensen T, Kautzky-Willer A, Kavousi M, Koenig W, Konradi A, Kotecha D, Landmesser U, Lettino M, Lewis BS, Linhart A, Løchen M-L, Makrilakis K, Mancia G, Marques-Vidal P, McEvoy JW, McGreavy P, Merkely B, Neubeck L, Nielsen JC, Perk J, Petersen SE, Petronio AS, Piepoli M, Pogosova NG, Prescott EIB, Ray KK, Reiner Z, Richter DJ, Rydén L, Shlyakhto E, Sitges M, Sousa-Uva M, Sudano I, Tiberi M, Touyz RM, Ungar A, Verschuren WMM, Wiklund O, Wood D, Zamorano JL, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford CA, Davos CH, Desormais I, Di Angelantonio E, Franco Duran OH, Halvorsen S, Richard Hobbs FD, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, Dis IV, van Gelder IC, Wanner C, Williams B. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227–3337. 10.1093/Feurheartj/Fehab484 - DOI - PubMed
    1. Cabac‐Pogorevici I, Muk B, Rustamova Y, Kalogeropoulos A, Tzeis S, Vardas P. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. Eur J Heart Fail 2020;22:789–799. 10.1002/Fejhf.1747 - DOI - PubMed
    1. Pastena P, Frye JT, Ho C, Goldschmidt ME, Kalogeropoulos AP. Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options. Heart Fail Rev 2024;29:287–299. 10.1007/Fs10741-023-10377-4 - DOI - PubMed
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol 2018;17:83. 10.1186/Fs12933-018-0728-6 - DOI - PMC - PubMed
    1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222. - PMC - PubMed

Publication types

MeSH terms

Substances